HSBC Innovation Banking’s Post

Delighted to announce we led a USD 130m Series C round at Enveda alongside our friends at FPV Ventures, with participation from Baillie Gifford and other new and existing investors. Many of the world's best selling drugs were derived from nature's chemistry, yet the last few decades of drug discovery have been focused on synthetic compounds. What if robotics and AI today allow us to sequence life's chemistry with more precision? Much like how genomics evolved over the last 20 years? Our thesis that Enveda will unlock the potential of life's chemistry and thereby discover and develop safer and more efficacious drugs is well underway, with speed to development candidate already at 4X industry average. We're excited to see the team deliver in the clinic next! Thanks for the amazing work and dedication team Enveda, onwards! Viswa Colluru, PhD Pegah Ebrahimi rohit sharma Zavain Dar Shaquille Vayda Bruce Beutel Ala Alenazi Kinnevik

So happy to share this update!!

Ligence, a Lithuanian-founded medical technology start-up, has successfully raised €3 million in investment. The main investors include Simpact Ventures, a venture capital fund manager from Poland, Coinvest Capital, the European Innovation Council Fund, Lemonade Stand, an Estonian venture capital firm, the NGL business angel syndicate, and private investor Rita Sakus. Ligence is developing artificial intelligence-based software for more detailed analysis of echocardiogram data. This funding will support the advancement of diagnostic solutions for heart disease. The COBALT team, led by partner Akvile Bosaite, provided legal support to the European Innovation Council Fund throughout the entire investment process. 🔊 Read more: https://shorturl.at/jAJMY

🌟 Biotech VC Landscape: Major Funds for Clinical Stage, Smaller Funds Driving Early Innovation 🌟 While big VC firms raise billions to back clinical-stage biotechs with proven leaders, smaller funds are fostering early-stage, experimental science and innovative teams. 💡 Firms like Wing VC and KdT Ventures are focusing on seed and Series A, funding biotech ideas that might just be tomorrow's game-changers. Early founders, though, face a high bar for proof, pushing them to optimise resources for maximum impact. 👀 The biotech space is leaning on strategic efficiency, resourcefulness, and selectivity more than ever! #BiotechFunding #VentureCapital #EarlyStageInnovation #LifeSciences

🚀 Facing challenges navigating the biotech funding landscape? 🧬 In this new episode of #BIOfromtheBAYOU, Ben Kromnick, Head of Healthcare and Life Sciences at Mercury, shares key insights on financing and scaling biotech companies. Learn how biotech startups can secure funding at various growth stages, innovate effectively, and build lasting relationships with investors and partners. 💡 Key takeaways include: • Strategies for securing funding at different stages of growth • The importance of innovation and partnerships in scaling • Lessons from Mercury’s work with biotech founders 🔗 Tune in to discover how Mercury is shaping the future of biotech financing. Link in comments! #BiotechFunding #StartupGrowth #BiotechInnovation #Mercury #Investors #TechTransfer

#ICYMI: MedTech Strategist/Market Pathways's own Stephen Levin will be moderating the "Successfully Navigating Exits and Financings in Tough Times" panel discussion between Earlybird Venture Capital's Dr. Christoph Massner and LimFlow SA's Dan Rose at MedTech Europe's The MedTech Forum 2024 on Thursday, May 23 at 10:40AM-11:30AM. Despite a challenging environment for M&A and fundraising amidst an evolving EU regulatory landscape, this panel features strategics, investors and start-up CEOs who are doing deals in spite of these obstacles, and are here to share their strategies in achieving these goals. Lean more here: https://lnkd.in/ex3Y9ySx #MTF2024 #conferences #paneldiscussion #medtech #medtechindustry #medtechinnovation #regulatory

New: 8VC, a tech and life sciences investor behind startups like longevity biotech Altos Labs, is raising a $1 billion fund. The Austin-based firm outlined the plans for the sixth fund in an SEC filing on Wednesday. #8VC #lifesciencesvc #biotechvc #healthvc #venturecapitalfund

Brandon Capital, a leading life sciences VC firm in Australia, has another AUD $270 million (~ $180 million) to support 15 to 20 startups in drug development, health tech and medical devices. While the US-to-Europe life sciences investing axis is well established at this point, with many biotech VCs supporting new drug developers from Boston to Basel and elsewhere across the pond, the path between Australasia and Europe is less trodden, Brandon Capital partner Jonathan Tobin said in an interview with Endpoints News. #lifesciences #biotechfunding #biotechstartups #australia #australasia #venturecapital

Don’t miss our interview with Christer Fåhraeus at the BioStock Life Science Summit!   Get an exclusive look at the vision behind Fåhraeus Startup and Growth Fund, a venture capital fund co-founded by Christer Fåhraeus and Emanuel Eriksson. In the interview, Christer shares how the fund focuses on investing early in life science and tech companies with high potential, supporting their growth journey.   Watch the interview now to learn more about their approach!

Dan Angius, Managing Director at Nasdaq, joined Inning 8: Exits: M&A & IPO, hosted by Christiaan Engstrom, founder and CEO of the Bullpen. "It seems as though the window for biotech has opened ahead of other sectors, including general healthcare. Why is that important? Well, actually, historically, when you see periods of IPO drought, one of the first catalysts that happened is that the healthcare market, specifically the biotech markets, are the first ones to wake up when we're coming out of the drought, because generally speaking, they're somewhat detached from overall market gyrations by virtue of science and phase results. We've been seeing that." View here: https://lnkd.in/gzTxXxf5 Each week leading up to BIO 2024 in San Diego, the Bullpen holds a virtual meeting (#BullpenInnings) featuring 10+ industry leaders. Keep up to date on the status of the market in the Bullpen and join us for Inning 9: Pitch Competition (May 29th, 2024 | 12-1PM ET), exclusive to Bullpen members only. Become a Member: https://lnkd.in/gKhx6SHN The #Bullpen is an invite-only, volunteer-led Club that gathers Life Science Investors and CxOs with a shared goal of helping each other. Our Mantra: Find someone to help. Repeat. https://lnkd.in/gN7rvyZP Interested in becoming a Club Member? Schedule a brief intro meeting with Bullpen Member Director Laura Farley, CRPC here: https://lnkd.in/gRNaBF85 Nola E. Masterson, Portfolia Femtech Funds, Vered Gigi, PhD, aMoon Fund, Dan Angius, Nasdaq, David H. Crean, Cardiff Advisory LLC, Anne DeGheest, HealthTech Capital, Susan Grant Schneider, MPS, Sequoia Biotech Consulting, Chris Mayo, CFA, LSEG (London Stock Exchange Group), Keara S., Sauber Capital, Andy Danielsen, Mayo Clinic, Jeff Steinle, Fredrikson & Byron, P.A.